Colony Stimulating Factor-1 Receptor Blocker class drugs
1 result
Niktimvo (axatilimab-csfr)
(axatilimab-csfr)Incyte Corporation
Usage: NIKTIMVO is indicated for treating chronic graft-versus-host disease (cGVHD) in adults and pediatric patients weighing at least 40 kg, after they have failed at least two prior lines of systemic therapy.